Amgen’s patent — opposed by COPA — is upheld by EPO Board of Appeal
MLex Summary: The European Patent Office’s Board of Appeal has upheld Amgen Inc’s patent for a method of preparing a drug, AMG 416, rejecting COPA Copenhagen Patents' opposition. COPA had argued that...To view the full article, register now.
Already a subscriber? Click here to view full article